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Atezolizumab in cisplatin-ineligible 
locally advanced/metastatic urothelial 
carcinoma: primary analysis of 
IMvigor210 cohort 1
Cisplatin-based chemotherapy is a standard fi rst-line 
treatment for metastatic urothelial carcinoma (mUC) 
and the only treatment that prolongs the median over-
all survival (mOS). Due to age or comorbidities, 30-50% 
of patients are ineligible for this regimen and receive no 
treatment. A total of 119 chemotherapy-naïve and cispl-
atin-ineligible mUC patients (renal glomerular fi ltration 
rate between 30 and 60 mL/min, hearing impairment, 
≥G2 peripheral neuropathy or ≥ Eastern Cooperative 
Oncology Group performance status [ECOG PS] 2) re-
ceived atezolizumab, an active and well tolerated immu-
notherapy in platinum-treated mUC, 1200 mg IV q3w 
until disease progression. The primary effi cacy endpoint 
was confi rmed objective response rate (ORR) according 
to the RECIST v1.1 criteria while the secondary end-
points included OS. In the cohort, 18% received prior 
systemic treatment; 10% previously had radiotherapy 
and 66% suffered from visceral metastases. The me-
dian follow-up in the study was 14.4 months (range 
0.2-20.1 months). The ORR for all patients was 24% 
(95% CI[16%-32%]) of which 7% had a complete re-
sponse (CR). Responses occurred in all investigated sub-
groups, irrespective of immune cell PD-L1 expression 
(ORR=21%, 25% and 28% for IC0, IC1/2/3 and IC2/3, 
respectively) (Figure 1) and poor prognostic factors. The 
mOS was 14.8 months (95%CI: 10.1 months - not es-
timable). Overall, atezolizumab was well tolerated with 
66% and 15% treatment-related all grade and grade 3/4 
adverse events (AEs), respectively. These data prove the 
clinical utility of atezolizumab in fi rst-line cisplatin-inel-
igible mUC patients, making it an attractive alternative 
to chemotherapy. Further research comparing atezoli-
zumab to chemotherapy in fi rst-line is however needed. 
CheckMate 032: effi cacy and safety of 
nivolumab monotherapy in metastatic 
urothelial carcinoma
Minimal activity of the existing therapies in combina-
tion with the demonstrated immune dysfunction in 
UC have prompted the evaluation of immunotherapy 
in this malignancy. Nivolumab, a fully human IgG4 
programmed death-1 (PD-1) immune checkpoint in-
hibitor antibody, previously demonstrated a survival 
benefi t in patients with melanoma, lung cancer, and 
renal cell carcinoma. Building on this success, the ef-
fi cacy and safety of this antibody was determined in 
a multicentre phase I/II study with mUC patients af-
ter ≥1 prior line of platinum-based therapy. Seventy-
eight patients received nivolumab 3 mg/kg IV q2w until 
progression or discontinuation. The primary endpoint 
was ORR (RECIST v1.1), while the other objectives in-
cluded safety, duration of response, progression-free 
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From June 3rd till June 8th, Chicago was host for the 52nd ASCO annual meeting. The theme for this year’s 
venue was ‘Collective Wisdom: The Future of Patient-Centred Care and Research’. With almost 35,000 
registered attendees from over 100 countries worldwide and about 6,000 submitted abstracts, this 
year’s meeting was a great success. This report will highlight 10 key studies concerning genitourinary 
cancers presented during the meeting. 





Announcement of a Breast Cancer Prevention Study 
in BRCA1&2 carriers 
Young BRCA1&2 carriers are kindly invited to participate in a scientific study 
 
 
Carriers of mutated BRCA1&2 genes have a lifetime risk of up to 70% to develop breast cancer.  Genome analysis of 
breast cells in these carriers demonstrates differences compared to women without elevated risk.  As a consequence 
on can state that women with a high risk for breast cancer develop a high-risk gene profile.  Recent findings from the 
Fox chase Cancer Center in Philadelphia (USA) indicate that is possible to convert high to low risk profiles with a rhCG 
(recombinant human Chorionic Gonadotropin) hormonal treatment. hCG strongly increases during pregnancy.  
Hence the name ‘pregnancy hormone’.  Previous research already indicated that an early full time pregnancy (e.g. 
between 18 and 24 years of age) effectively protects against breast cancer.  Treatment with rhCG proved an efficient 
simulation of full time pregnancy. 
Safe 
rhCG has already been explored in the 90ties in breast cancer patients.  Not only the treatment (a subcutaneous 
injection 3x per week during 12 weeks) proved efficient in early and advanced breast cancer but safe as well.  There 
were indeed no reportable side effects.  
Study conduct 
The study can be summarized as follows: 
 No costs 
 Consultation to evaluate study inclusion 
 36 subcutaneous injections with rhCG (Ovidrel) in a period of 12 weeks: 3 times a week 
 3 tissue examinations (before, after and 24 weeks after treatment) to evaluate individual risk profile for 
breast cancer and to explore the decrease of risk after treatment 
The study can be offered in every center.  Participants will also be referred back to the treating physician once the 
study has been terminated. The study can be a milestone in the fight against breast cancer. 
More info 
www.ecpo.org or sabine.janssens@ecprevention.org 
 
Prof. Herman Depypere Prof. Eric de Jonge Prof. Jaak Janssens 
UZ Gent ZOL Genk ECP Hasselt 
 












































Y-axis demonstrates the maximum sum of the longest diameter reduction from baseline (%). RECIST v1.1 responses are demonstrated: progressive 
disease (grey bars), stable disease (dark blue bars), partial response (light blue bars) and complete response (red bars).
Figure 1. Effi cacy of atezolizumab in mUC across subgroups according to immune cell PD-L1 expression.1
survival (PFS), and OS. With a median follow-up of 
9.0 months (range 0.7-16.6 months), 23.1% of patients 
remained on nivolumab monotherapy. The ORR was 
24.4% (95%CI: 15.3%-35.4%) with a CR in 6.4% and 
a mPFS of 2.8 months (95%CI: 1.5-5.9 months). The 
median OS in this study was 9.7 months (95%CI: 7.3-
16.2 months). The level of tumoral PD-L1 expression 
(<1% or ≥1%) was not correlated with the ORR, with 
an ORR of 26.2% in patients with a PD-L1 expression 
<1% and of 24.0% in the subgroup expressing PD-L1 
in ≥1% of the cells (Figure 2). Grade 3/4 treatment-re-
lated AEs occurred in 22% of patients, with increased 
lipase, fatigue, maculopapular rash and nausea as most 
frequently reported AEs. 
In summary, nivolumab monotherapy demonstrated 
promising effi cacy and acceptable safety in previous-
ly treated mUC patients and could become a treatment 
option in these patients.2
Safety and effi cacy of durvalumab in 
urothelial carcinoma
Another possible immunotherapy candidate in UC 
consists of the modifi ed human IgG1 mAb durvalum-
ab, blocking the PD-L1 binding to PD-1 and CD80. 
In total 61 inoperable or mUC patients (ECOG PS 
0-1), who did not previously receive an anti-PD-1/PD-
L1 agent, were treated with durvalumab 10 mg/kg IV 
q2w for up to 12 months. The primary endpoint was 
ORR (RECIST v1.1). Half of patients (51%) received ≥2 
prior systemic treatments. After a median follow-up of 
6.5 months (range 0.8-14.8 months), 42 patients were 
evaluable for response, demonstrating an ORR 31% 
(N=13). Tumour and immune cell PD-L1 expression 
both appeared to independently enrich for treatment 
response as all responders were tumour or immune cell 
PD-L1 positive (Figure 3). Currently, 12 patients con-
tinue to respond to treatment with the longest dura-
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tion of response ongoing after more than 11.3 months. 
Drug-related AEs occurred in 64% of patients with fa-
tigue and diarrhoea as the most frequently reported 
AEs. Only 5 drug-related grade 3/4 AEs were report-
ed. Durvalumab showed an acceptable safety profi le 
with evidence of clinical activity in heavily pretreated 
UC patients.3
Together with previous described studies, immunother-










































PD-L1 ≥1% PD-L1 not quantifiable




































PD-L1 + PD-L1 -
X-axis represents patients, Y-axis demonstrates the maximum sum of the longest diameter reduction from baseline (%). Subgroups are demonstrated: tumour or immune cell 
PD-L1 expression ≥25% (blue bars) and tumour or immune cell PD-L1 expression <25% (green bars). *Unconrmed response,     unconventional response
Figure 2. Effi cacy of nivolumab in mUC across subgroups according to tumour PD-L1 expression.2
Figure 3. Effi cacy of nivolumab in mUC across subgroups according to tumour PD-L1 expression.2
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CHAARTED: quality of life analysis in 
chemo-hormonal androgen ablation for 
prostate cancer
Previously, androgen deprivation therapy (ADT) plus 
docetaxel for metastatic hormone sensitive prostate can-
cer was shown to improve the mOS as compared to ADT 
alone. However, docetaxel shows multiple AEs that can 
diminish the quality of life (QoL). In this study, 790 
prostate cancer patients were randomised 1:1 to 6 cy-
cles ADT plus docetaxel or ADT. The QoL was assessed 
at baseline and 3, 6, 9 and 12 months post randomi-
sation and compared between both study arms. ADT 
plus docetaxel was associated with signifi cantly worse 
FACT-P scores at 3 months (p=0.02), yet signifi cantly 
better scores were reported after 12 months of therapy 
(p=0.04). Also FACIT-fatigue at 3 months was worse 
in patients who received ADT plus docetaxel (p=0.01) 
compared to ADT. However, after 12 months no differ-
ence was observed (p=0.32). FACT-taxane scores were 
lower in patients receiving ADT plus docetaxel (p<0.02). 
BPI scores did not differ signifi cantly between arms over 
time. Emotional well-being was better in patients on 
ADT plus docetaxel at all time points (p<0.01). 
In summary although ADT plus docetaxel was associ-
ated with a decreased QoL at 3 months, the 12-month 
QoL was better for patients receiving ADT plus docetax-
el compared to ADT alone.4
Survival results from the PRINCE phase 
III trial
This randomised phase III trial investigated the non-
inferiority of intermittent docetaxel compared to a con-
tinuous docetaxel treatment for patients with metastatic 
castration-resistant prostate cancer (mCRPC). A total of 
156 eligible patients were randomised 1:1 to docetax-
el IV 35 mg/m² q1w or 70 mg/m² q3w. Continuous 
docetaxel was given until discontinuation while the in-
termittent arm received docetaxel for 12 weeks and then 
paused until clinical disease progression (increased se-
rum PSA >4 µg/L with a 50% increase over baseline 
level, radiological or symptomatic progression). The 
primary endpoint was one-year OS rate, with OS, PFS, 
median time to treatment failure and toxicity as key sec-
ondary endpoints. The one-year survival rate was 75% 
(95%CI: 64%-85%) in the continuous arm as compared 
























HR = 1.14 (95% CI, 0.75 to 1.72; P = .535)
Figure 4. Overall survival of continuous versus intermittent docetaxel in CRPC. No difference was observed in one-year 
OS or in mOS between continuous and intermittent docetaxel regimen in CRPC.5
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so the median OS was comparable between both arms: 
18.3 vs. 19.3 months (p=0.535) (Figure 4). No signifi-
cant difference was observed in median PFS or time to 
treatment failure and the safety profile was comparable 
for both study arms. As such, intermittent docetaxel 
was shown to be non-inferior to a continuous therapy 
with respect to one-year survival and could represent a 
treatment option for patients with mCRPC.5
PROSELICA: Non-inferiority in overall 
survival for different doses of 
cabazitaxel in mCRPC
Cabazitaxel showed utility in mCRPC patients previ-
ously treated with docetaxel.6 In the presented phase 
III study the efficacy and safety profile of 2 different 
doses of cabazitaxel was determined in 1,200 mCRPC 
patients who progressed after treatment with docetaxel. 
Patients with an ECOG PS of 0–2 were randomised 1:1 
to cabazitaxel 20 mg/m² IV q3w (C20, N=598) or ca-
bazitaxel 25 mg/m² IV q3w (C25, N=602). Both groups 
additionally received prednisone 10 mg PO daily. The 
primary endpoint was OS, while secondary endpoints 
included PFS, PSA response, ORR and AEs. Both the 
median OS (13.4 vs. 14.5 months) and median PFS (2.9 
vs. 3.5 months) did not differ significantly between C20 
and C25 (Figure 5). Of note, a subgroup analysis fa-
voured C25 in patients who received prior enzalutamide 
or abiraterone acetate therapy, although this was not 
significant. In contrast to the findings in OS and PFS, 
the PSA response (42.9% vs. 29.5%) and ORR (23.4% vs. 
18.5%) were notably higher in C25 as compared to C20. 
Grade 3/4 AEs were reported more frequently with C25 
(54.5%) as compared to C20 (39.7%).7
In summary, the non-inferiority to C25 and the im-
proved overall safety profile makes C20 a candidate as 
treatment option in this cohort of patients.
Comparing cabazitaxel to docetaxel: 
overall survival results from the 
FIRSTANA trial
In contrast to PROSELICA, another study assessed 
the clinical utility of cabazitaxel in chemotherapy-na-
ive mCRPC patients, with little to no patients hav-
ing received prior enzalutamide or abiraterone acetate 
treatment. In this three-arm phase III trial 1,168 chemo-
therapy-naive patients were randomised 1:1:1 to C20 
(N=391) or C25 (N=389) or docetaxel 75 mg/m² IV 
q3w (N=388). All groups additionally received pred-
nisone 10 mg PO daily. The primary endpoint was OS, 
while secondary endpoints included safety, PFS, tumour 
response (according to RECIST v1.1), PSA response, 
time to skeletal-related events and QoL. At the time of 
the analysis, the median OS was 24.5 months for C20, 
25.2 months for C25 and 24.3 months for docetaxel. 
Resulting hazard ratios were 1.01 (95%CI: 0.85-1.20; 
p=0.997) for C20 vs. docetaxel and 0.97 (95%CI: 0.82-
1.16, p=0.757) for C25 vs. docetaxel. The median PFS 
was 4.4 months for C20, 5.1 months for C25 and 5.3 
months for docetaxel (p>0.05). The rate of tumour re-
sponse was superior in C25 (41.6%) as compared to 
docetaxel (30.9%) (p=0.037) while all other secondary 
endpoints did not differ significantly across the patient 
cohorts. Grade 3/4 AEs were observed in 41.2% in C20, 


























0 63 129 1815 2421 3027 36 3933 42 45 48
No. at Risk:
CBZ 20+PRED 598 469 393 324 210 109 55 30 9 0



























0 63 129 1815 2421 3027 36 3933 42 45 48
No. at Risk:
CBZ 20+PRED 598 469 393 324 210 109 55 30 9 0
CBZ 25+PRED 602 494 416 338 219 120 58 25 11 0
Figure 5. Overall (left) and progression free survival (right) of different cabazitaxel regimens in mCRPC. No difference 
was observed in mOS or in mPFS between both regimens.7
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mostly febrile neutropenia, diarrhoea and haematuria 
in C20/25 compared to peripheral neuropathy, periph-
eral oedema, alopecia and nail disorders in docetaxel. 
The authors concluded that C20 and C25 did not dem-
onstrate superiority for OS compared to docetaxel in 
mCRPC patients.8
Correlation between the androgen 
receptor splice variant 7 and efficacy of 
abiraterone and enzalutamide
It was previously reported that an association existed 
between androgen receptor splice variant 7 (AR-V7) 
detection and poor outcomes with abiraterone and 
enzalutamide in mCRPC patients.9 At ASCO 2016, an 
expanded analysis of the study was presented. A total 
of 202 mCRPC patients were enrolled and the prognos-
tic value of circulating tumour cell (CTC) detection and 
AR-V7 detection was examined. Endpoints consisted of 
PSA response, PFS and OS. CTC positive and AR-V7 
positive patients (N=36) were found to be more like-
ly to have a Gleason score ≥8 (p=0.050), present with 
metastatic disease at diagnosis (p=0.01), have higher 
PSA concentrations (p<0.01) and were more likely to 
have received prior treatment with abiraterone/enzalu-
tamide (p=0.03), or with a taxane (p=0.02). Overall, 
these patients exhibited lower PSA responses (14% vs. 
52%) and had a shorter median PFS (3.1 vs. 7.1 months) 
and median OS (11.2 vs. 29.5 months) than CTC pos-
itive and AR-V7 negative patients (all p<0.001). This 
observation was also true in both first- and second-line 
novel hormonal therapy. The authors therefore suggest 
that the CTC-based AR-V7 assay should be interpret-
ed using 3 separate prognostic categories namely CTC 
negative, CTC positive / AR-V7 negative and CTC pos-
itive / AR-V7 positive.10
Final overall survival results from the 
METEOR trial
Last year, Choueiri et al. reported that the tyrosine ki-
nase inhibitor cabozantinib (which inhibits MET, VEGF 
receptors, and AXL) significantly improved the PFS and 
the ORR as compared to everolimus in previously treat-
ed RCC patients.11 At ASCO 2016, the final OS data 
of this trial were presented. At the primary analysis, 
658 patients with measurable clear cell RCC, Karnofsky 
performance status ≥70, and ≥1 prior VEGFR tyrosine 
kinase inhibitor were randomised 1:1 to cabozantinib 
(60 mg PO daily) or everolimus (10 mg PO daily). Pa-
tients were stratified by MSKCC risk group and num-
ber of prior VEGFR tyrosine kinase inhibitors (1 or ≥2). 
The median OS was 21.4 months as compared to 16.5 
months. This translates into a 33% reduction in the rate 
of death (HR[95%CI]: 0.67[0.53-0.83]; p=0.0003) (Fig-
ure 6A). Landmark estimates of survival at 18 months 
were 58% in the cabozantinib arm vs. 47% in the evero-
limus arm. The OS benefit with cabozantinib was con-
sistently observed across all pre-specified subgroups, 
including MSKCC risk group (Figure 6B-D), number of 
prior VEGFR tyrosine kinase inhibitors, prior anti-PD-1/
PD-L1 treatment and location and extent of tumour me-
tastases. Furthermore, the median PFS remained higher 
in the cabozantinib group (7.4 months) as compared to 
the everolimus group (3.9 months, p<0.0001). 
As such, this analysis demonstrated that cabozantinib 
is the only agent to demonstrate a significant benefit in 
OS, PFS, and ORR in a phase III trial with previously 
treated advanced or mRCC patients making it an impor-
tant new treatment option for these patients.12
Summary of long-term overall survival 
of nivolumab in previously treated RCC 
patients
The clinical utility of nivolumab in mRCC was reported 
in the phase III CheckMate 025 study with a significant-
ly longer median OS for nivolumab than with everolim-
us.13 At ASCO 2016, the nivolumab long-term OS results 
from a phase I and II study were reported. In the phase I 
study, 34 advanced RCC patients (ECOG PS≤2 and 1 to 
5 prior systemic treatments) received nivolumab (1 or 10 
mg/kg) q2w. After a minimum follow-up of 50.5 months, 
ORR was 29% and the median duration of response was 
12.9 months. The 4- and 5-year OS rates were 38% and 
34%.14 In the phase II study, 167 advanced RCC patients 
(Karnofsky performance status ≥70 and 1 to 3 prior sys-
temic treatments) received nivolumab (0.3, 2, or 10 mg/
kg) q3w. At a minimum follow-up of 38.0 months, the 
ORR was 21.6%, the median duration of response was 
23.0 months and the 4-year OS rate was 29%.15
Furthermore, also in the CheckMate 025 trial, pro-
longed survival during treatment with nivolumab was 
observed disregarding the MSKCC risk group, Kar-
nofsky performance status or best response to thera-
py. With approximately 1/3 of patients alive still at 5 
years in the phase I study and at 4 years in the phase 
II study, this is the longest follow-up reported to date 
with any anti-PD-1/PD-L1 agent in RCC. Potential pre-
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dictors of long-term survival in this patient population 
are being explored.16
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Figure 6. Overall survival of cabozantinib compared to everolimus in mRCC. A significant difference was observed in 
median OS (A) between the cabozantinib and everolimus cohort. This differences was observed among favourable (B), 
intermediate (C) and poor risk groups (D).12
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Key messages for clinical practice
1. Immunotherapy will become a viable treatment option in metastatic urothelial cancer as various 
anti-PD-1/PD-L1 inhibitors show clinical utility in both chemotherapy-naïve and (heavily) 
pretreated patients.
2. Androgen deprivation therapy plus docetaxel proves better quality of life over androgen 
deprivation therapy alone, in hormone responsive metastatic prostate cancer patients, despite 
a reduction in the quality of life during the first 3 months of therapy.
3. Intermittent docetaxel in mCRPC is non-inferior to the continuous regimen and could be 
presented as a treatment option for patients, although this did not result in less toxicity. 
4. Cabazitaxel was not demonstrated to be superior to docetaxel for treatment of mCRPC. The 
improved safety profile of 20 mg/m² cabazitaxel versus 25 mg/m² cabazitaxel, makes the former 
a candidate as second line chemotherapy.
5. Use of the androgen receptor splice variant 7 in mCRPC can predict response to therapy in both first- 
and second-line novel hormonal therapy.
6. Cabozantinib improves the PFS and OS in metastatic renal cell carcinoma, making this drug an 
important new treatment option.
7. Long-term survival data of nivolumab confirm the possibility of a shift in the therapeutic land-
scape of metastatic renal cell carcinoma.
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